Edit
ADCendo ApS
https://adcendo.dk/Last activity: 30.04.2021
Probably Closed - Reference to Adcendo
Adcendo aps is a biotech company developing novel targeted anti-cancer therapies based on antibody-drug conjugates (adcs).
Location: Denmark, Capital Region of Denmark, Copenhagen
Total raised: $61.86M
Investors 2
| Date | Name | Website |
| 29.04.2021 | Gilde Heal... | gildehealt... |
| - | Ysios Capi... | ysioscapit... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.04.2021 | Series A | $61.86M | Ysios Capi... |
Mentions in press and media 4
| Date | Title | Description |
| 30.04.2021 | Adcendo raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers | Copenhagen, Denmark, 29 April 2021 – Adcendo, a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a EUR 51 million (US$ 62 million) Series A financing. The inv... |
| 29.04.2021 | Adcendo raises €51M series A round to pursue 'ideal' ADC target | Adcendo has raised a €51 million ($62 million) series A round to develop antibody-drug conjugates (ADCs). The Novo Seeds-Ysios Capital-led financing positions Adcendo to take an anti-uPARAP ADC to clinical proof of concept in cancer patient... |
| 29.04.2021 | Adcendo Raises EUR 51M in Series A Financing | Adcendo, a Copenhagen, Denmark-based biotech company which is developing antibody-drug conjugates (ADCs) for the treatment of cancers, raised EUR 51m (US$ 62m) in Series A financing. The round was led by Novo Seeds and Ysios Capital, with p... |
| 29.04.2021 | Ysios Capital leads a €51M round in Adcendo, also followed up by Novo Seeds, RA Capital Management, HealthCap and Gilde | ADCENDO RAISES €51 MILLION IN SERIES A FINANCING TO ADVANCE NOVEL ANTIBODY-DRUG CONJUGATES FOR TREATMENT OF CANCERS. Financing led by Novo Seeds and Ysios Capital is largest Series A for a Danish biotech company Plans to build a pipeline o... |